8-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
10-Q - Vivani Medical, Inc. (0001266806) (Filer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Vivani's GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously announced sham-implant adjusted preclinical weight loss of 20%, which is comparable to the weight loss produced from the semaglutide (active ingredient in Ozempic®/Wegovy®) injection control arm in the same study Clinical development of Vivani's exenatide implant in overweight and obese patients as part of the Company's NPM-115 program remains on track to commence in the fourth quarter of 2024 Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical co
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York. Vivani's Chief Executive Officer, Adam Mendelsohn, Ph.D., will host one-on-one meetings with investors at the Conference in addition to providing an overview of the Company. Details of this presentation are as follows: Date: Wednesday, September 11, 2024 Time: 10-10:30 a.m. Eastern Time Location: Adams Room (Fourth floor), Lotte New York Palace, New York, NY
Initiation of the NPM-115 clinical program expected in the fourth quarter of 2024 with a first-in-human study evaluating a miniature, subdermal GLP-1 (exenatide) implant in obese or overweight patients FDA provided clearance of the Investigational New Drug Application for NPM-119, providing further confidence to advance the Company's emerging portfolio of GLP-1 implants into clinical phase development Solid financial position supports operations into the second half of 2025 and potential delivery of key portfolio milestones Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported fina
SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)
SC 13D - Vivani Medical, Inc. (0001266806) (Subject)